皮层厚度对肝素吸收的影响
C Kroon1, A de Boer, J M Kroon
1Centre for Human Drug Research, University Hospital, Leiden, Netherlands.
Lancet (London, England)
|April 20, 1991
概括
从皮下注射的肝素吸收显示出显著的个体变化,与腹部皮厚度有关. 这一发现影响了肝素治疗和预防策略.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 氨酸是一种广泛使用的抗凝剂.
- 了解肝素吸收对于有效的剂量至关重要.
研究的目的:
- 为了评估高分子量和低分子量肝素分量的皮下吸收.
- 为了确定影响肝素吸收变化的因素.
主要方法:
- 八名健康的男性接受了静脉注射和皮下肝素.
- 通过抗Xa,抗血活性和激活的部分血栓形成时间监测的抗凝血.
- 记录了体重,脂肪和皮厚度.
主要成果:
- 观察到高分子量和低分子量氨酸分片的类似吸收.
- 皮下肝素吸收的显著个体间变异.
- 腹部皮厚度与吸收变异性相关.
结论:
- 皮下肝素的吸收在个体之间是高度变化的.
- 腹部皮的厚度是影响肝素吸收的关键因素.
- 这些发现对优化肝素治疗和预防方案具有重要意义.
相关概念视频
Factors Influencing Drug Absorption: Anatomical Parameters
Drug absorption involves the movement of drugs from the point of administration into the systemic circulation. Initially, Gastrointestinal (GI) motility propels the drug through the digestive tract and into the stomach. However, the stomach's high acidity and limited surface area restrict its role in drug absorption for most drugs. The drug then moves from the stomach to the small intestine via gastric emptying, which can be slowed by various factors, including interactions with other...
Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...


